Journal
NEUROLOGICAL SCIENCES
Volume 33, Issue 2, Pages 275-279Publisher
SPRINGER
DOI: 10.1007/s10072-011-0701-6
Keywords
Clinically nonfunctioning pituitary adenoma; Dopamine 2 receptor; Prolactinoma; Messenger ribonucleic acid; Real-time RT-PCR
Categories
Funding
- National Natural Science Foundation of China [30800347]
- Wenzhou Science and Technology Bureau [Y20080226]
- Zhejiang Provincial Natural Science Foundation of China [R2091137]
- Zhejiang Provincial Program for the Cultivation of High-level Innovative Health talents
Ask authors/readers for more resources
Dopamine receptor agonists (DAs) can reduce hormone release and tumor mass in the majority of prolactinomas, whereas such effects are controversial in clinically nonfunctioning pituitary adenomas (NFPAs). Whether expression of dopamine 2 receptor (D2R) is different in subgroups of NFPAs has not been fully elucidated. We assessed and compared D2R subtype (long: D2L and short: D2S) mRNA levels in subgroups of NFPAs by real-time reverse transcriptase polymerase chain reaction (RT-PCR). For both D2L and D2S mRNA, there were no significant differences among them. Only 21.6% of NFPAs showed relatively high D2R mRNA levels; furthermore, histopathological subtypes of those cases with relatively high D2R expression were gonadotropinomas and null-cell adenomas. These data suggest that DAs are effective only for a small proportion of NFPAs, and relatively high D2R expression may more possibly happen to a subset of gonadotropinomas and null-cell adenomas.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available